LoadingLoadingLoadingNet selling: insiders sold $84.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
Balyasny
$34.8M
added
Point72
$30.4M
bought
Sells/Trims (1)
Citadel
$50.6M
trimmed
No tracked top-trader positions in BNTX as of Oct 24, 04:54 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
-$2.58 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$0.42 to $1.35
Revenue expected
11 analysts
Last 30 days
Analysts raising estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | -$3.03 / -$2.58Alpha Vantage | -17.44% miss | EUR 105.6M No estimate | Unavailable |
| Mar 31, 2026 | May 5, 2026 | -$1.95 / -$1.92Alpha Vantage | -1.56% miss | EUR 120.0M No estimate | Unavailable |
| Dec 31, 2025 | Mar 10, 2026 | -$0.33 / -$0.25Alpha Vantage | -33.50% miss | EUR 898.9M No estimate | Unavailable |
| Sep 30, 2025 | Nov 3, 2025 | -$0.12 / $0.10Alpha Vantage | -$0.22 miss | EUR 1.52B No estimate | Unavailable |
| Jun 30, 2025 | Aug 4, 2025 | -$1.60 / -$1.41Alpha Vantage | -13.48% miss | EUR 260.8M No estimate | Unavailable |
| Mar 31, 2025 | May 5, 2025 | -$1.73 / -$2.35Alpha Vantage | +26.38% beat | EUR 182.8M No estimate | Unavailable |
| Dec 31, 2024 | Mar 10, 2025 | $1.08 / $0.48Alpha Vantage | +126.56% beat | EUR 1.19B No estimate | Unavailable |
| Sep 30, 2024 | Nov 4, 2024 | $0.81 / -$1.61Alpha Vantage | +$2.42 beat | EUR 1.24B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
This company is not yet profitable.
Valuation
Quality
Growth
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bearish
BioNTech (BNTX) and Bristol Myers Squibb plan to replace chemotherapy in a breast cancer trial, pending approval.
Leans bullishOct 22BioNTech plans the first global late-stage test of a cancer-drug pairing, pending approval
BullishOct 22BofA cuts BioNTech stock target from USD 122.00 to USD 114.00
BearishOct 20Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch
Leans bearishOct 19BioNTech (BNTX) will present first results for two cancer drug combinations
BullishOct 19BioNTech Faces Setbacks in Clinical Trials Amid Pipeline Hopes
Leans bearishOct 18BioNTech SE Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - BNTX
BearishOct 16BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)
BearishOct 14
